

I hereby certify that this correspondence is being transmitted via the Office electronic filing system to the U.S. Patent and Trademark Office, on the date shown below.

Dated: October 31, 2009

Signature: Mark D. Russett  
Mark D. Russett, Reg. No. 41,281

Docket No.: 62936(46342)  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Takafumi Ishii et al.

Application No.: 10/525,105

Confirmation No.: 2820

Filed: October 25, 2005

Art Unit: 1642

For: PREVENTIVES/REMEDIES FOR  
CANCER

Examiner: L. Yao

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam:

In accordance with 37 CFR 1.97, Applicant(s) hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicant(s) have become aware of the following documents, cited in an Office Action issued August 4, 2009, during the prosecution of Japanese Patent Application No. 2003-296081, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submit(s) these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed as well. A copy of the Japanese Office Action (including an English translation thereof) is also enclosed (see citation CD on the enclosed PTO Form SB/08).

A concise explanation of relevance of the items listed on form PTO/SB/08 is given for only non-English language listed items: For citation CD (Japanese Office Action dated August 4, 2009 in corresponding Japanese patent application no. 2003-296081), see the enclosed English translation. For citations CA-CC, in addition to the cited publication, see the discussion in the Japanese Office Action.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicant(s) understand(s) the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Please charge our Deposit Account No. 04-1105 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 62936(46342).

Dated: October 31, 2009

Respectfully submitted,

By: /Mark D. Russett/

Mark D. Russett, Registration No.: 41,281

EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 239-0100

Attorneys/Agents For Applicants